Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma
- 14 April 2006
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 342 (3), 824-828
- https://doi.org/10.1016/j.bbrc.2006.02.044
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose RegimensCancer Research, 2004
- Cancer Anti-angiogenic TherapyBiological & Pharmaceutical Bulletin, 2004
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals Of Oncology, 2002
- Redefining the Target: Chemotherapeutics as AntiangiogenicsJournal of Clinical Oncology, 2001
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJCI Insight, 2000
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJCI Insight, 2000
- Treatment of Non-Small-Cell Lung Cancer With Prolonged Oral EtoposideAmerican Journal of Clinical Oncology, 1998
- Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.Journal of Clinical Oncology, 1998
- Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agentsInvestigational New Drugs, 1997
- Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanismEuropean Journal of Cancer and Clinical Oncology, 1991